Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2009

View Archived Issues

Tetraphase presents novel, potent tetracycline and pentacycline analogues at ICAAC meeting

International Medica Foundation starts phase II clinical trial for rotavirus vaccine

Dynavax initiates phase III trial of hepatitis B vaccine Heplisav in chronic kidney disease

NIH awards Novelos Therapeutics and MGH grant to study NOV-002 and NOV-205

Icagen initiates proof-of-mechanism study in U.K. of ICA-105665 in pain

BioCryst initiates phase II study of PNP inhibitor BCX-4208 for treatment of gout

Eisai and DNDi sign collaboration and license agreement for E-1224 for Chagas disease

Acrux reports results from phase III trial of Axiron in testosterone deficiency

Alimera reports 18-month safety and efficacy results from phase II PK study of Iluvien in DME

Motesanib evaluated in combination therapy in advanced solid tumors

Novel glycopetide antibacterial agent LT-00029 shows potent in vitro and in vivo activity

Novacta presents preclinical data on its novel lantibiotic NVB-302 in C. difficile infection

Novel skeletal protein and muscle modulators disclosed by Cytokinetics

Roche submits filing to EMEA to extend indication of RoActemra in rheumatoid arthritis

Roche initiates dosing in phase Ib study of ITMN-191 in chronic HCV genotype-1

Resverlogix reports results from phase Ib/IIa clinical trial of RVX-208

Marshall Edwards reports results from in vivo studies of NV-128 in animal xenograft models

Bayer and Onyx report results from phase II trial of Nexavar and paclitaxel in breast cancer

LifeCycle reports results from a 12-month extension segment of the phase II LCP-Tacro study

Antimicrobial MUT-056399 enters phase I study, preclinical activity described

Orexigen Therapeutics reports results from phase IIb trial of Empatic for obesity

Experiments detail activity of EGFR, erbB2 and erbB3 signalling inhibitor AZD-8931

Fovea to be acquired by sanofi-aventis

rHuPH20 accelerates insulin absorption in patients with type 1 diabetes

Roche describes alpha1A-adrenoceptor partial agonists for urinary incontinence

Janssen identifies FAAH inhibitors for the treatment of pain and other conditions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...